Search clinical trials for: REGN5381

Total 5 results

Regeneron Pharmaceuticals

Completed

Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Adult Humans

Healthy

Belgium
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn How REGN5381 Works and How Safe it is in Adults With Heart Failure With Reduced Ejection Fraction (HFrEF)

Heart Failure

Moldova, Republic of
Regeneron Pharmaceuticals

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Adult Volunteers and Mildly Hypertensive Participants

Healthy Volunteers

Germany, Belgium
Regeneron Pharmaceuticals

Recruiting

REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure

Heart Failure

Turkey, Moldova, Republic of, Hungary, Belgium, Poland, Romania
Regeneron Pharmaceuticals

Recruiting

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Participants With Aggressive B-cell Non-Hodgkin Lymphomas (ATHENA-1)

B-cell Non-Hodgkins Lymphoma (B-NHL)

United States, United Kingdom

3

Subscribe